In 2026, U.S. agreements lower costs of GLP-1 drugs for obesity and diabetes, impacting Medicare and Medicaid coverage with a focus on starter dose affordability and access limitations.

A study finds that nearly 65% of users of weight loss drugs like Ozempic quit due to high costs and limited insurance coverage. Understanding the challenges in affordability and access is crucial to improve health outcomes.